Macular Oedema Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Macular Oedema clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 3

Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

Severe Diabetic Macular Oedema
Belfast Health and Social Care Trust264 enrolled22 locationsNCT06985706
Recruiting
Not Applicable

Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery

Cataract SurgeryNSAID (Non-Steroidal Anti-Inflammatory Drug)Macular Oedema
Nemocnice Kolín150 enrolled1 locationNCT07178639
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME)

Diabetic Macular Oedema
Innovent Biologics Technology Limited (Shanghai R&D Center)150 enrolled1 locationNCT06908876
Recruiting
Phase 4

Aflibercept for Diabetic Macular Oedema: Outcomes Using a Treat and Extend Protocol

Diabetic Macular Oedema
The Royal Adelaide Hospital50 enrolled2 locationsACTRN12619000963123
Recruiting

A Randomised Multi-centre Placebo Controlled Trial of Fenofibrate for Treatment of Diabetic Macular Oedema with Economic Evaluation (FORTE Study)

Diabetic Macular Oedema
University of Sydney392 enrolled1 locationACTRN12618000592246
Recruiting
Phase 4

Intravitreal Aflibercept for the Treatment of Treatment Resistant Macular Oedema secondary to Retinal Vein Occlusions

macular oedema secondary to retinal vein occlusion
A/Prof Andrew Chang50 enrolled1 locationACTRN12617001487303
Recruiting
Phase 4

Intravitreal Aflibercept for the Treatment of Treatment Resistant Diabetic Macular Oedema

Diabetic Macular Oedema
Andrew Chang50 enrolled1 locationACTRN12614001307695
Recruiting
Phase 2

Avastin versus Triamcinolone for Diabetic Macular Edema at the time of Cataract Surgery

CataractsDiabetic Macular Oedema
Royal Victorian Eye and Ear Hospital100 enrolled1 locationACTRN12611000888965
Recruiting
Phase 2

A phase II, 12 month, randomized, sham-controlled trial of ranibizumab (Lucentis) combined with grid laser compared with laser alone for the treatment of recalcitrant, diabetic macular oedema.

Diabetic RetinopathyDiabetic Macular Oedema
Novartis40 enrolled1 locationACTRN12611000063910